

Bruce D Cheson

List of Publications by Year in Descending Order

Source: <https://exaly.com/author-pdf/2038669/bruce-d-cheson-publications-by-year.pdf>

Version: 2024-04-27

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

323
papers

31,415
citations

59
h-index

176
g-index

357
ext. papers

35,565
ext. citations

3.8
avg, IF

6.83
L-index

#	Paper	IF	Citations
323	Comparative analysis of targeted novel therapies in relapsed, refractory chronic lymphocytic leukaemia. <i>Haematologica</i> , 2021 , 106, 284-287	6.6	1
322	Current Role of Functional Imaging in the Management of Lymphoma. <i>Current Oncology Reports</i> , 2021 , 23, 144	6.3	1
321	Identification of a genetic signature enriching for response to ibrutinib in relapsed/refractory follicular lymphoma in the DAWN phase 2 trial. <i>Cancer Medicine</i> , 2021 ,	4.8	1
320	Biomarkers for Risk Stratification in Patients With Previously Untreated Follicular Lymphoma Receiving Anti-CD20-based Biological Therapy. <i>American Journal of Surgical Pathology</i> , 2021 , 45, 384-393	6.7	3
319	Phase II study of acalabrutinib in ibrutinib-intolerant patients with relapsed/refractory chronic lymphocytic leukemia. <i>Haematologica</i> , 2021 , 106, 2364-2373	6.6	21
318	Diffuse large B-cell lymphoma: new targets and novel therapies. <i>Blood Cancer Journal</i> , 2021 , 11, 68	7	13
317	Umbralisib, a Dual PI3K/CK1 Inhibitor in Patients With Relapsed or Refractory Indolent Lymphoma. <i>Journal of Clinical Oncology</i> , 2021 , 39, 1609-1618	2.2	36
316	CALGB 50801 (Alliance): PET adapted therapy in bulky stage I/II classic Hodgkin lymphoma (cHL).. <i>Journal of Clinical Oncology</i> , 2021 , 39, 7507-7507	2.2	3
315	Recent Advances in the Management of Patients with Relapsed/Refractory Follicular Lymphoma. <i>Blood and Lymphatic Cancer: Targets and Therapy</i> , 2021 , 11, 55-66	2.6	1
314	Phase 2 study of the safety and efficacy of umbralisib in patients with CLL who are intolerant to BTK or PI3K Inhibitor therapy. <i>Blood</i> , 2021 , 137, 2817-2826	2.2	19
313	Copanlisib in the Treatment of Relapsed Follicular Lymphoma: Utility and Experience from the Clinic. <i>Cancer Management and Research</i> , 2021 , 13, 677-692	3.6	2
312	Prognostic value of interim FDG-PET in diffuse large cell lymphoma: results from the CALGB 50303 Clinical Trial. <i>Blood</i> , 2020 , 135, 2224-2234	2.2	37
311	Impact of idelalisib on health-related quality of life in patients with relapsed chronic lymphocytic leukemia in a phase III randomized trial. <i>Haematologica</i> , 2020 , 105, e519	6.6	3
310	Assessment of the Efficacy of Therapies Following Venetoclax Discontinuation in CLL Reveals BTK Inhibition as an Effective Strategy. <i>Clinical Cancer Research</i> , 2020 , 26, 3589-3596	12.9	43
309	Bortezomib consolidation or maintenance following immunochemotherapy and autologous stem cell transplantation for mantle cell lymphoma: CALGB/Alliance 50403. <i>American Journal of Hematology</i> , 2020 , 95, 583-593	7.1	7
308	Successful Treatment of Ocular Chronic Lymphocytic Leukemia with Ibrutinib: Case Report and Review of the Literature. <i>Leukemia Research Reports</i> , 2020 , 14, 100200	0.6	0
307	Long-Term Follow-up of CALGB (Alliance) 100001: Autologous Followed by Nonmyeloablative Allogeneic Transplant for Multiple Myeloma. <i>Biology of Blood and Marrow Transplantation</i> , 2020 , 26, 1414-1424	4.7	3

306	Umbralisib, the Once Daily Dual Inhibitor of PI3K and Casein Kinase-1 Demonstrates Clinical Activity in Patients with Relapsed or Refractory Indolent Non-Hodgkin Lymphoma: Results from the Phase 2 Global Unity-NHL Trial. <i>Blood</i> , 2020 , 136, 34-35	2.2	5
305	Ibrutinib and Venetoclax in Relapsed and Refractory Follicular Lymphoma. <i>Blood</i> , 2020 , 136, 46-47	2.2	3
304	Investigational CD47-Blocker TTI-622 Shows Single-Agent Activity in Patients with Advanced Relapsed or Refractory Lymphoma: Update from the Ongoing First-in-Human Dose Escalation Study. <i>Blood</i> , 2020 , 136, 46-47	2.2	7
303	Ongoing, first-in-human, phase I dose escalation study of the investigational CD47-blocker TTI-622 in patients with advanced relapsed or refractory lymphoma.. <i>Journal of Clinical Oncology</i> , 2020 , 38, 3030-3030	2.2	5
302	Phase II, multicenter trial of nivolumab (Nivo) and brentuximab vedotin (BV) in patients (Pts) with untreated Hodgkin lymphoma (HL) over the age of 60 years or unable to receive standard ABVD chemotherapy: Results of a study of Academic and Community Cancer Research United (ACCRU) N10515051. <i>Journal of Clinical Oncology</i> , 2020 , 38, 8014-8014	2.2	3
301	Myeloablative versus non-myeloablative consolidative chemotherapy for newly diagnosed primary central nervous system lymphoma: Results of induction therapy in Alliance 51101.. <i>Journal of Clinical Oncology</i> , 2020 , 38, 8042-8042	2.2	0
300	Functional Imaging in Hodgkin Lymphoma. <i>Hematologic Malignancies</i> , 2020 , 113-143	0	
299	Relevance of bone marrow biopsies for response assessment in NCTN follicular lymphoma clinical trials.. <i>Journal of Clinical Oncology</i> , 2020 , 38, 8038-8038	2.2	0
298	The efficacy and safety of venetoclax therapy in elderly patients with relapsed, refractory chronic lymphocytic leukaemia. <i>British Journal of Haematology</i> , 2020 , 188, 918-923	4.5	10
297	Acalabrutinib monotherapy in patients with Waldenström macroglobulinemia: a single-arm, multicentre, phase 2 study. <i>Lancet Haematology</i> , 2020 , 7, e112-e121	14.6	65
296	Copanlisib in the treatment of non-Hodgkin lymphoma. <i>Future Oncology</i> , 2020 , 16, 1947-1955	3.6	6
295	The Impact of Age on Survival in CLL Patients Receiving Ibrutinib as Initial Therapy. <i>Blood and Lymphatic Cancer: Targets and Therapy</i> , 2020 , 10, 1-5	2.6	1
294	MRD response in relapsed/refractory FL after obinutuzumab plus bendamustine or bendamustine alone in the GADOLIN trial. <i>Leukemia</i> , 2020 , 34, 522-532	10.7	11
293	Management of Adverse Events From the Combination of Rituximab and Lenalidomide in the Treatment of Patients With Follicular and Low-Grade Non-Hodgkin Lymphoma. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2020 , 20, 563-571	2	7
292	Randomized trial of ofatumumab and bendamustine versus ofatumumab, bendamustine, and bortezomib in previously untreated patients with high-risk follicular lymphoma: CALGB 50904 (Alliance). <i>Cancer</i> , 2019 , 125, 3378-3389	6.4	4
291	Final Results of a Randomized, Phase III Study of Rituximab With or Without Idelalisib Followed by Open-Label Idelalisib in Patients With Relapsed Chronic Lymphocytic Leukemia. <i>Journal of Clinical Oncology</i> , 2019 , 37, 1391-1402	2.2	109
290	Tumor Lysis, Adverse Events, and Dose Adjustments in 297 Venetoclax-Treated CLL Patients in Routine Clinical Practice. <i>Clinical Cancer Research</i> , 2019 , 25, 4264-4270	12.9	37
289	Polatuzumab vedotin or pinatuzumab vedotin plus rituximab in patients with relapsed or refractory non-Hodgkin lymphoma: final results from a phase 2 randomised study (ROMULUS). <i>Lancet Haematology</i> , 2019 , 6, e254-e265	14.6	108

288	Dose-Adjusted EPOCH-R Compared With R-CHOP as Frontline Therapy for Diffuse Large B-Cell Lymphoma: Clinical Outcomes of the Phase III Intergroup Trial Alliance/CALGB 50303. <i>Journal of Clinical Oncology</i> , 2019 , 37, 1790-1799	2.2	156
287	Utility of positron emission tomography-computed tomography in patients with chronic lymphocytic leukemia following B-cell receptor pathway inhibitor therapy. <i>Haematologica</i> , 2019 , 104, 2258-2264	6.6	16
286	Phase 2 multicentre study of single-agent ofatumumab in previously untreated follicular lymphoma: CALGB 50901 (Alliance). <i>British Journal of Haematology</i> , 2019 , 185, 53-64	4.5	6
285	Targeting Biology in Non-Hodgkin Lymphoma. <i>Hematology/Oncology Clinics of North America</i> , 2019 , 33, 727-738	3.1	1
284	Safety and Efficacy of Atezolizumab in Combination with Rituximab Plus CHOP in Previously Untreated Patients with Diffuse Large B-Cell Lymphoma (DLBCL): Updated Analysis of a Phase I/II Study. <i>Blood</i> , 2019 , 134, 2874-2874	2.2	14
283	Sustained Overall Survival Benefit of Obinutuzumab Plus Bendamustine Followed By Obinutuzumab Maintenance Compared with Bendamustine Alone in Patients with Rituximab-Refractory Indolent Non-Hodgkin Lymphoma: Final Results of the Gadalim Study. <i>Blood</i> , 2019 , 134, 2822-2822	2.2	1
282	Efficacy of Therapies Following Venetoclax Discontinuation in CLL: Focus on B-Cell Receptor Signal Transduction Inhibitors and Cellular Therapies. <i>Blood</i> , 2019 , 134, 502-502	2.2	4
281	Treatment Sequences and Outcomes of Patients with CLL Treated with Venetoclax and Other Novel Agents Post Introduction of Novel Therapies. <i>Blood</i> , 2019 , 134, 1756-1756	2.2	1
280	A Phase Ib, Open-Label, Randomized Study to Assess Safety and Preliminary Efficacy of Tafasitamab (MOR208) or Tafasitamab + Lenalidomide in Addition to R-CHOP in Patients with Newly Diagnosed Diffuse Large B-Cell Lymphoma: The First-Mind Trial. <i>Blood</i> , 2019 , 134, 2877-2877	2.2	3
279	Toxicities and Outcomes of Acalabrutinib-Treated Patients with Chronic Lymphocytic Leukemia: A Retrospective Analysis of Real World Patients. <i>Blood</i> , 2019 , 134, 4311-4311	2.2	12
278	Phase 1/2 trial of acalabrutinib plus pembrolizumab (Pem) in relapsed/refractory (r/r) diffuse large B-cell lymphoma (DLBCL).. <i>Journal of Clinical Oncology</i> , 2019 , 37, 7519-7519	2.2	8
277	Phase 2 study of acalabrutinib in ibrutinib (IBR)-intolerant patients (pts) with relapsed/refractory (R/R) chronic lymphocytic leukemia (CLL).. <i>Journal of Clinical Oncology</i> , 2019 , 37, 7530-7530	2.2	7
276	Long-Term Follow-up of Follicular Lymphoma (FL) Patients (pts) Demonstrating Undetectable Minimal Residual Disease (MRD) Using a Next-Generation Based DNA Assay: Support for FL As a Curable Disease. <i>Blood</i> , 2019 , 134, 2813-2813	2.2	
275	North American Practice Patterns for PET-2 Positive Hodgkin Lymphoma. <i>Blood</i> , 2019 , 134, 1553-1553	2.2	
274	Treatment Discontinuation Patterns for Patients with CLL in the Real-World Settings: Results from a Multi-Center Study. <i>Blood</i> , 2019 , 134, 3048-3048	2.2	
273	A retrospective comparison of venetoclax alone or in combination with an anti-CD20 monoclonal antibody in R/R CLL. <i>Blood Advances</i> , 2019 , 3, 1568-1573	7.8	18
272	Introduction by the Guest Editor: Staying Ahead of the Rapidly Evolving World of Chronic Lymphocytic Leukemia. <i>Cancer Journal (Sudbury, Mass)</i> , 2019 , 25, 373	2.2	
271	Targeted Therapies in Chronic Lymphocytic Leukemia: Is 2 (or 3) Better Than 1?. <i>Cancer Journal (Sudbury, Mass)</i> , 2019 , 25, 449-454	2.2	0

270	The prognostic significance of PFS24 in follicular lymphoma following firstline immunotherapy: A combined analysis of 3 CALGB trials. <i>Cancer Medicine</i> , 2019 , 8, 165-173	4.8	15
269	Venetoclax for chronic lymphocytic leukaemia patients who progress after more than one B-cell receptor pathway inhibitor. <i>British Journal of Haematology</i> , 2019 , 185, 961-966	4.5	6
268	Combinations or sequences of targeted agents in CLL: is the whole greater than the sum of its parts (Aristotle, 360 BC)?. <i>Blood</i> , 2019 , 133, 121-129	2.2	13
267	Optimal Management of Adverse Events From Copanlisib in the Treatment of Patients With Non-Hodgkin Lymphomas. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2019 , 19, 135-141	2	27
266	Descriptive analysis of genetic aberrations and cell of origin in Richter transformation. <i>Leukemia and Lymphoma</i> , 2019 , 60, 971-979	1.9	1
265	Frequency and impact of grade three or four toxicities of novel agents on outcomes of older patients with chronic lymphocytic leukemia and non-Hodgkin lymphoma (alliance A151611). <i>Journal of Geriatric Oncology</i> , 2018 , 9, 321-328	3.6	4
264	Toxicities and outcomes of 616 ibrutinib-treated patients in the United States: a real-world analysis. <i>Haematologica</i> , 2018 , 103, 874-879	6.6	219
263	iwCLL guidelines for diagnosis, indications for treatment, response assessment, and supportive management of CLL. <i>Blood</i> , 2018 , 131, 2745-2760	2.2	607
262	PET/CT in Lymphoma: Current Overview and Future Directions. <i>Seminars in Nuclear Medicine</i> , 2018 , 48, 76-81	5.4	30
261	CALGB 50604: risk-adapted treatment of nonbulky early-stage Hodgkin lymphoma based on interim PET. <i>Blood</i> , 2018 , 132, 1013-1021	2.2	59
260	Surrogate Endpoints and Risk Adaptive Strategies in Previously Untreated Follicular Lymphoma. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2018 , 18, 447-451	2	2
259	Outcomes of front-line ibrutinib treated CLL patients excluded from landmark clinical trial. <i>American Journal of Hematology</i> , 2018 , 93, 1394-1401	7.1	37
258	Determining the sequence of novel therapies in the treatment of relapsed Hodgkin's lymphoma. <i>Expert Review of Hematology</i> , 2018 , 11, 773-780	2.8	1
257	Speaking volumes about volumes. <i>Blood</i> , 2018 , 131, 2408-2409	2.2	1
256	Real-world outcomes and management strategies for venetoclax-treated chronic lymphocytic leukemia patients in the United States. <i>Haematologica</i> , 2018 , 103, 1511-1517	6.6	91
255	Bortezomib Maintenance (BM) or Consolidation (BC) Following Aggressive Immunochemotherapy and Autologous Stem Cell Transplant (ASCT) for Untreated Mantle Cell Lymphoma (MCL): 8 Year Follow up of CALGB 50403 (Alliance). <i>Blood</i> , 2018 , 132, 146-146	2.2	5
254	Venetoclax As Monotherapy or in Combination: Patterns of Use and Predictors of Outcomes in an International Multicenter Study of CLL Patients. <i>Blood</i> , 2018 , 132, 3142-3142	2.2	2
253	Safety and Efficacy of Atezolizumab in Combination with Rituximab Plus CHOP in Previously Untreated Patients with Diffuse Large B-Cell Lymphoma (DLBCL): Primary Analysis of a Phase I/II Study. <i>Blood</i> , 2018 , 132, 2969-2969	2.2	7

252	The dual SYK/JAK inhibitor cerdulatinib demonstrates rapid tumor responses in a phase 2 study in patients with relapsed/refractory B- and T-cell non-Hodgkin lymphoma (NHL).. <i>Journal of Clinical Oncology</i> , 2018 , 36, 7511-7511	2.2	6
251	A phase 2 study to assess the safety and efficacy of umbralisib (TGR-1202) in pts with CLL who are intolerant to prior BTK or PI3K inhibitor therapy.. <i>Journal of Clinical Oncology</i> , 2018 , 36, 7530-7530	2.2	5
250	Racial, age, and sex disparities in chronic lymphocytic leukemia (CLL) patients treated with novel therapies.. <i>Journal of Clinical Oncology</i> , 2018 , 36, 6577-6577	2.2	
249	A U.S.-based survey: The experiences of 1147 chronic lymphocytic leukemia (CLL) patients (pts).. <i>Journal of Clinical Oncology</i> , 2018 , 36, 7532-7532	2.2	
248	Adverse Events, Patterns of Tumor Lysis Syndrome Prophylaxis and Management, and Dosing Patterns in a Large Cohort of Venetoclax Treated CLL Patients in Community and Academic Settings. <i>Blood</i> , 2018 , 132, 4410-4410	2.2	
247	Factors That Influence Treatment Decision-Making: Perspectives of 1147 Chronic Lymphocytic Leukemia (CLL) Patients in the United States. <i>Blood</i> , 2018 , 132, 4414-4414	2.2	1
246	Identification of a Genetic Signature Enriching for Response to Ibrutinib in Relapsed/Refractory Follicular Lymphoma in the Dawn Phase 2 Trial. <i>Blood</i> , 2018 , 132, 4147-4147	2.2	
245	Venetoclax for chronic lymphocytic leukaemia progressing after ibrutinib: an interim analysis of a multicentre, open-label, phase 2 trial. <i>Lancet Oncology</i> , 2018 , 19, 65-75	21.7	228
244	Continued Excellent Outcomes in Previously Untreated Patients With Follicular Lymphoma After Treatment With CHOP Plus Rituximab or CHOP Plus I-Tositumomab: Long-Term Follow-Up of Phase III Randomized Study SWOG-S0016. <i>Journal of Clinical Oncology</i> , 2018 , 36, 697-703	2.2	50
243	Overall Survival Benefit in Patients With Rituximab-Refractory Indolent Non-Hodgkin Lymphoma Who Received Obinutuzumab Plus Bendamustine Induction and Obinutuzumab Maintenance in the GADOLIN Study. <i>Journal of Clinical Oncology</i> , 2018 , 36, 2259-2266	2.2	73
242	Ibrutinib as Treatment for Patients With Relapsed/Refractory Follicular Lymphoma: Results From the Open-Label, Multicenter, Phase II DAWN Study. <i>Journal of Clinical Oncology</i> , 2018 , 36, 2405-2412	2.2	55
241	A phase 1 study of lenalidomide and ibrutinib in combination with rituximab in relapsed and refractory CLL. <i>Blood Advances</i> , 2018 , 2, 762-768	7.8	13
240	Recommendations for Clinical Trial Development in Follicular Lymphoma. <i>Journal of the National Cancer Institute</i> , 2017 , 109,	9.7	16
239	Overestimated value of FDG-PET based bone marrow evaluation in lymphoma: Response to Adams and Kwee. <i>British Journal of Haematology</i> , 2017 , 179, 337-339	4.5	1
238	Long-term outcomes, secondary malignancies and stem cell collection following bendamustine in patients with previously treated non-Hodgkin lymphoma. <i>British Journal of Haematology</i> , 2017 , 178, 2502-2506	4.5	22
237	Pros and cons of rituximab maintenance in follicular lymphoma. <i>Cancer Treatment Reviews</i> , 2017 , 58, 34-40	14.4	7
236	Safety and tolerability of idelalisib, lenalidomide, and rituximab in relapsed and refractory lymphoma: the Alliance for Clinical Trials in Oncology A051201 and A051202 phase 1 trials. <i>Lancet Haematology</i> , 2017 , 4, e176-e182	14.6	66
235	Health-related quality of life and symptoms in patients with rituximab-refractory indolent non-Hodgkin lymphoma treated in the phase III GADOLIN study with obinutuzumab plus bendamustine versus bendamustine alone. <i>Annals of Hematology</i> , 2017 , 96, 253-259	3	15

234	RB but not R-HCVAD is a feasible induction regimen prior to auto-HCT in frontline MCL: results of SWOG Study S1106. <i>British Journal of Haematology</i> , 2017 , 176, 759-769	4.5	26
233	Patterns of growth factor usage and febrile neutropenia among older patients with diffuse large B-cell non-Hodgkin lymphoma treated with CHOP or R-CHOP: the Intergroup experience (CALGB 9793; ECOG-SWOG 4494). <i>Leukemia and Lymphoma</i> , 2017 , 58, 1814-1822	1.9	9
232	Impact of obinutuzumab alone and in combination for follicular lymphoma. <i>Blood and Lymphatic Cancer: Targets and Therapy</i> , 2017 , 7, 73-83	2.6	0
231	Tumor Lysis Syndrome in Chronic Lymphocytic Leukemia with Novel Targeted Agents. <i>Oncologist</i> , 2017 , 22, 1283-1291	5.7	39
230	What Is the Role of Chemotherapy in Patients With Chronic Lymphocytic Leukemia?. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2017 , 17, 723-727	2	4
229	Extended Follow-up of Patients Treated With Bendamustine for Lymphoid Malignancies. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2017 , 17, 637-644	2	10
228	Investigator and independent review committee exploratory assessment and verification of tumor response in a non-Hodgkin lymphoma study. <i>Leukemia and Lymphoma</i> , 2017 , 58, 1332-1340	1.9	2
227	Phase I Study of the Anti-CD22 Antibody-Drug Conjugate Pinatuzumab Vedotin with/without Rituximab in Patients with Relapsed/Refractory B-cell Non-Hodgkin Lymphoma. <i>Clinical Cancer Research</i> , 2017 , 23, 1167-1176	12.9	50
226	Analysis of PET-CT to Identify Richter's Transformation in 167 Patients with Disease Progression Following Kinase Inhibitor Therapy. <i>Blood</i> , 2017 , 130, 834-834	2.2	10
225	Evidence of low incidence of myelodysplastic syndrome (MDS) in patients exposed to bendamustine treatment for chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL).. <i>Journal of Clinical Oncology</i> , 2017 , 35, e19008-e19008	2.2	3
224	KI intolerance study: A phase 2 study to assess the safety and efficacy of TGR-1202 in pts with chronic lymphocytic leukemia (CLL) who are intolerant to prior BTK or PI3K-delta inhibitor therapy.. <i>Journal of Clinical Oncology</i> , 2017 , 35, TPS7569-TPS7569	2.2	
223	Refinement of the Lugano Classification lymphoma response criteria in the era of immunomodulatory therapy. <i>Blood</i> , 2016 , 128, 2489-2496	2.2	235
222	PI3K signaling pathway in normal B cells and indolent B-cell malignancies. <i>Seminars in Oncology</i> , 2016 , 43, 647-654	5.5	24
221	Obinutuzumab plus bendamustine versus bendamustine monotherapy in patients with rituximab-refractory indolent non-Hodgkin lymphoma (GADOLIN): a randomised, controlled, open-label, multicentre, phase 3 trial. <i>Lancet Oncology, The</i> , 2016 , 17, 1081-1093	21.7	224
220	The role of idelalisib in the treatment of relapsed and refractory chronic lymphocytic leukemia. <i>Therapeutic Advances in Hematology</i> , 2016 , 7, 69-84	5.7	21
219	(18) F-FDG PET-CT and trephine biopsy assessment of bone marrow involvement in lymphoma. <i>British Journal of Haematology</i> , 2016 , 174, 410-6	4.5	22
218	Optimal use of bendamustine in hematologic disorders: Treatment recommendations from an international consensus panel - an update. <i>Leukemia and Lymphoma</i> , 2016 , 57, 766-82	1.9	56
217	Early Relapse of Follicular Lymphoma after Rituximab-Based Biologic Doublet Upfront Therapy Is Associated with Increased Risk of Death: A Combined Analysis from CALGB Studies 50402, 50701 and 50803 (Alliance). <i>Blood</i> , 2016 , 128, 2953-2953	2.2	3

216	Preliminary Results of a Phase 1b Dose Escalation and Dose Expansion Study of GS-4059 in Combination with Idelalisib in Subjects with B-Cell Malignancies. <i>Blood</i> , 2016 , 128, 2961-2961	2.2	1
215	Pseudo-Progression Among Patients with Follicular Lymphoma Treated with Ibrutinib in the Phase 2 DAWN Study. <i>Blood</i> , 2016 , 128, 2980-2980	2.2	2
214	Serum Biomarkers Predict Outcomes in Advanced Hodgkin Lymphoma Independent of International Prognostic Score (IPS) and Treatment: Correlative Analysis from a Large North American Cooperative Group Trial. <i>Blood</i> , 2016 , 128, 2992-2992	2.2	3
213	Toxicities and Outcomes of Ibrutinib-Treated Patients in the United States: Large Retrospective Analysis of 621 Real World Patients. <i>Blood</i> , 2016 , 128, 3222-3222	2.2	16
212	Optimal Sequencing of Ibrutinib, Idelalisib, and Venetoclax in CLL: Results from a Large Multi-Center Study of 683 US-Patients. <i>Blood</i> , 2016 , 128, 4400-4400	2.2	2
211	Phase III Randomized Study of R-CHOP Versus DA-EPOCH-R and Molecular Analysis of Untreated Diffuse Large B-Cell Lymphoma: CALGB/Alliance 50303. <i>Blood</i> , 2016 , 128, 469-469	2.2	73
210	Toxicities and Related Outcomes of Elderly Patients (pts) (≥5 Years) with Hematologic Malignancies in the Contemporary Era (Alliance A151611). <i>Blood</i> , 2016 , 128, 536-536	2.2	1
209	Obinutuzumab plus Bendamustine Followed by Obinutuzumab Maintenance Prolongs Overall Survival Compared with Bendamustine Alone in Patients with Rituximab-Refractory Indolent Non-Hodgkin Lymphoma: Updated Results of the GADOLIN Study. <i>Blood</i> , 2016 , 128, 615-615	2.2	14
208	Continued Excellent Outcomes in Previously Untreated Follicular Lymphoma Patients after Treatment with CHOP Plus Rituximab or CHOP Plus (131) Iodine-Tositumomab - Long Term Follow-up of Phase III Randomized Study SWOG S0016. <i>Blood</i> , 2016 , 128, 616-616	2.2	2
207	Venetoclax (VEN) Monotherapy for Patients with Chronic Lymphocytic Leukemia (CLL) Who Relapsed after or Were Refractory to Ibrutinib or Idelalisib. <i>Blood</i> , 2016 , 128, 637-637	2.2	43
206	Outcomes of CLL patients treated with sequential kinase inhibitor therapy: a real world experience. <i>Blood</i> , 2016 , 128, 2199-2205	2.2	135
205	Phase 1 trial of rituximab, lenalidomide, and ibrutinib in previously untreated follicular lymphoma: Alliance A051103. <i>Blood</i> , 2016 , 128, 2510-2516	2.2	45
204	US Intergroup Trial of Response-Adapted Therapy for Stage III to IV Hodgkin Lymphoma Using Early Interim Fluorodeoxyglucose-Positron Emission Tomography Imaging: Southwest Oncology Group S0816. <i>Journal of Clinical Oncology</i> , 2016 , 34, 2020-7	2.2	184
203	Phase 2 study of idelalisib and entospletinib: pneumonitis limits combination therapy in relapsed refractory CLL and NHL. <i>Blood</i> , 2016 , 127, 2411-5	2.2	113
202	Speed bumps on the road to a chemotherapy-free world for lymphoma patients. <i>Blood</i> , 2016 , 128, 325-302	2.2	16
201	Letter From the Editor: From 2003 to today. <i>Clinical Advances in Hematology and Oncology</i> , 2016 , 14, 646	0.6	
200	Letter From the Editor: Fellowship interviews and more. <i>Clinical Advances in Hematology and Oncology</i> , 2016 , 14, 742	0.6	1
199	Letter From the Editor: Ode to Bob. <i>Clinical Advances in Hematology and Oncology</i> , 2016 , 14, 838	0.6	

198	Letter From the Editor: The end. <i>Clinical Advances in Hematology and Oncology</i> , 2016 , 14, 942	0.6	
197	Advances in the treatment of follicular lymphoma. <i>Expert Opinion on Orphan Drugs</i> , 2015 , 3, 207-218	1.1	
196	Phase II Intergroup Trial of Alisertib in Relapsed and Refractory Peripheral T-Cell Lymphoma and Transformed Mycosis Fungoides: SWOG 1108. <i>Journal of Clinical Oncology</i> , 2015 , 33, 2399-404	2.2	82
195	Randomized Phase III Trial Comparing ABVD Plus Radiotherapy With the Stanford V Regimen in Patients With Stages I or II Locally Extensive, Bulky Mediastinal Hodgkin Lymphoma: A Subset Analysis of the North American Intergroup E2496 Trial. <i>Journal of Clinical Oncology</i> , 2015 , 33, 1936-42	2.2	24
194	A phase I study of bendamustine, lenalidomide and rituximab in relapsed and refractory lymphomas. <i>British Journal of Haematology</i> , 2015 , 169, 528-33	4.5	12
193	What is the status of novel anti-CD20 antibodies for chronic lymphocytic leukemia and are they set to leave rituximab in the shadows?. <i>Expert Review of Hematology</i> , 2015 , 8, 733-42	2.8	8
192	Randomized Trial of Lenalidomide Alone Versus Lenalidomide Plus Rituximab in Patients With Recurrent Follicular Lymphoma: CALGB 50401 (Alliance). <i>Journal of Clinical Oncology</i> , 2015 , 33, 3635-40	2.2	139
191	Ofatumumab and bendamustine in previously treated chronic lymphocytic leukemia and small lymphocytic lymphoma. <i>Leukemia and Lymphoma</i> , 2015 , 56, 915-20	1.9	26
190	Therapy with bortezomib plus lenalidomide for relapsed/refractory mantle cell lymphoma: final results of a phase II trial (CALGB 50501). <i>Leukemia and Lymphoma</i> , 2015 , 56, 958-64	1.9	31
189	Evaluation of the International Prognostic Score (IPS-7) and a Simpler Prognostic Score (IPS-3) for advanced Hodgkin lymphoma in the modern era. <i>British Journal of Haematology</i> , 2015 , 171, 530-8	4.5	39
188	Rethinking clinical response and outcome assessment in a biologic age. <i>Current Oncology Reports</i> , 2015 , 17, 27	6.3	2
187	Reply to B. Bennani-Baiti et al, H.J.A. Adams et al, E. Laffon et al, and E.A. Hawkes et al. <i>Journal of Clinical Oncology</i> , 2015 , 33, 1221-3	2.2	3
186	Reply to G. Keramida et al. <i>Journal of Clinical Oncology</i> , 2015 , 33, 4121-2	2.2	1
185	Primary Results of the Health-Related Quality of Life Assessment from the Phase III Gadolin Study of Obinutuzumab Plus Bendamustine Compared with Bendamustine Alone in Patients with Rituximab-Refractory, Indolent Non-Hodgkin Lymphoma. <i>Blood</i> , 2015 , 126, 1532-1532	2.2	4
184	Phase II Trial of Ofatumumab (OFA) in Previously Untreated Follicular Non-Hodgkin Lymphoma (NHL): CALGB 50901 (Alliance). <i>Blood</i> , 2015 , 126, 2741-2741	2.2	3
183	Interfollicular CD10 Expression and Follicular PD1 Tumor-Infiltrating Lymphocytes As Biologic Risk Factors in Patients with Previously Untreated Follicular Lymphoma Receiving Rituximab-Based Biologic Therapy: An Alliance Correlative Science Study (CALGB 50901, 50402, 50701, 50803, 50904). <i>Clinical Cancer Research</i> , 2015 , 21, 221-221	2.2	2
182	Bortezomib Maintenance (BM) Versus Consolidation (BC) Following Aggressive Immunochemotherapy and Autologous Stem Cell Transplant (ASCT) for Untreated Mantle Cell Lymphoma (MCL): CALGB (Alliance) 50403. <i>Blood</i> , 2015 , 126, 337-337	2.2	21
181	Analysis of Minimal Residual Disease in Follicular Lymphoma Patients in Gadolin, a Phase III Study of Obinutuzumab Plus Bendamustine Versus Bendamustine in Relapsed/Refractory Indolent Non-Hodgkin Lymphoma. <i>Blood</i> , 2015 , 126, 3978-3978	2.2	17

180	Phase I Study of Rituximab, Lenalidomide, and Ibrutinib in Previously Untreated Follicular Lymphoma (Alliance 051103). <i>Blood</i> , 2015 , 126, 471-471	2.2	5
179	Pre-Transplant R-Bendamustine Induces High Rates of Minimal Residual Disease in MCL Patients: Updated Results of S1106: US Intergroup Study of a Randomized Phase II Trial of R-HCVAD Vs. R-Bendamustine Followed By Autologous Stem Cell Transplants for Patients with Mantle Cell Lymphoma. <i>Blood</i> , 2015 , 126, 518-518	2.2	4
178	Initial Results of US Intergroup Trial of Response-Adapted Chemotherapy or Chemotherapy/Radiation Therapy Based on PET for Non-Bulky Stage I and II Hodgkin Lymphoma (HL) (CALGB/Alliance 50604). <i>Blood</i> , 2015 , 126, 578-578	2.2	18
177	Favorable Outcomes in CLL Pts with Alternate Kinase Inhibitors Following Ibrutinib or Idelalisib Discontinuation: Results from a Large Multi-Center Study. <i>Blood</i> , 2015 , 126, 719-719	2.2	9
176	Two doses of polatuzumab vedotin (PoV, anti-CD79b antibody-drug conjugate) in patients (pts) with relapsed/refractory (RR) follicular lymphoma (FL): Durable responses at lower dose level.. <i>Journal of Clinical Oncology</i> , 2015 , 33, 8503-8503	2.2	13
175	GADOLIN: Primary results from a phase III study of obinutuzumab plus bendamustine compared with bendamustine alone in patients with rituximab-refractory indolent non-Hodgkin lymphoma.. <i>Journal of Clinical Oncology</i> , 2015 , 33, LBA8502-LBA8502	2.2	9
174	Staging and response assessment in lymphomas: the new Lugano classification. <i>Chinese Clinical Oncology</i> , 2015 , 4, 5	2.3	77
173	Long-Term Outcomes, Secondary Malignancies, and Stem Cell Collection Following Bendamustine in Patients with Previously Treated Indolent Non-Hodgkin Lymphoma. <i>Blood</i> , 2015 , 126, 3961-3961	2.2	
172	Patterns of Lymphocytosis in Patients with Chronic Lymphocytic Leukemia (CLL) or Small Lymphocytic Lymphoma (SLL) Treated with Idelalisib. <i>Blood</i> , 2015 , 126, 2952-2952	2.2	
171	The creative destruction of medicine. <i>Clinical Advances in Hematology and Oncology</i> , 2015 , 13, 12	0.6	
170	Letter From the Editor: The return of the emperor. <i>Clinical Advances in Hematology and Oncology</i> , 2015 , 13, 271	0.6	
169	Letter From the Editor: Reflections on Lugano. <i>Clinical Advances in Hematology and Oncology</i> , 2015 , 13, 409	0.6	
168	Lymphoma: looking from the present to the future. <i>Chinese Clinical Oncology</i> , 2015 , 4, 2	2.3	
167	Idelalisib and rituximab in relapsed chronic lymphocytic leukemia. <i>New England Journal of Medicine</i> , 2014 , 370, 997-1007	59.2	1303
166	Current role of FDG PET/CT in lymphoma. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2014 , 41, 1004-27	8.8	51
165	Improved efficacy using rituximab and brief duration, high intensity chemotherapy with filgrastim support for Burkitt or aggressive lymphomas: cancer and Leukemia Group B study 10002. <i>British Journal of Haematology</i> , 2014 , 165, 102-11	4.5	68
164	PET-CT restaging: a surrogate for follicular lymphoma?. <i>Lancet Haematology, the</i> , 2014 , 1, e2-3	14.6	1
163	Recommendations for initial evaluation, staging, and response assessment of Hodgkin and non-Hodgkin lymphoma: the Lugano classification. <i>Journal of Clinical Oncology</i> , 2014 , 32, 3059-68	2.2	2407

162	CALGB 150905 (Alliance): rituximab broadens the antilymphoma response by activating unlicensed NK cells. <i>Cancer Immunology Research</i> , 2014 , 2, 878-89	12.5	42
161	A phase I study of PRO131921, a novel anti-CD20 monoclonal antibody in patients with relapsed/refractory CD20+ indolent NHL: correlation between clinical responses and AUC pharmacokinetics. <i>Clinical Immunology</i> , 2014 , 154, 37-46	9	22
160	Role of imaging in the staging and response assessment of lymphoma: consensus of the International Conference on Malignant Lymphomas Imaging Working Group. <i>Journal of Clinical Oncology</i> , 2014 , 32, 3048-58	2.2	927
159	Which Hodgkin's patients in the Unites States should be treated with BEACOPP?. <i>Current Hematologic Malignancy Reports</i> , 2014 , 9, 222-6	4.4	1
158	Bendamustine in the treatment of chronic lymphocytic leukemia. <i>Expert Opinion on Orphan Drugs</i> , 2014 , 2, 617-623	1.1	2
157	CLL and NHL: the end of chemotherapy?. <i>Blood</i> , 2014 , 123, 3368-70	2.2	9
156	Bendamustine: role and evidence in lymphoma therapy, an overview. <i>Leukemia and Lymphoma</i> , 2014 , 55, 1471-8	1.9	12
155	A phase II study of dacetuzumab (SGN-40) in patients with relapsed diffuse large B-cell lymphoma (DLBCL) and correlative analyses of patient-specific factors. <i>Journal of Hematology and Oncology</i> , 2014 , 7, 44	22.4	59
154	Unexpected and Serious Toxicity Observed with Combined Idelalisib, Lenalidomide and Rituximab in Relapsed/Refractory B Cell Lymphomas: Alliance A051201 and A051202. <i>Blood</i> , 2014 , 124, 3091-3091	2.2	28
153	Second Interim Analysis of a Phase 3 Study of Idelalisib (ZYDELIG [®]) Plus Rituximab (R) for Relapsed Chronic Lymphocytic Leukemia (CLL): Efficacy Analysis in Patient Subpopulations with Del(17p) and Other Adverse Prognostic Factors. <i>Blood</i> , 2014 , 124, 330-330	2.2	54
152	Updated Results of a Phase II Randomized Study (ROMULUS) of Polatuzumab Vedotin or Pinatuzumab Vedotin Plus Rituximab in Patients with Relapsed/Refractory Non-Hodgkin Lymphoma. <i>Blood</i> , 2014 , 124, 4457-4457	2.2	24
151	Efficacy of idelalisib in CLL subpopulations harboring del(17p) and other adverse prognostic factors: Results from a phase 3, randomized, double-blind, placebo-controlled trial.. <i>Journal of Clinical Oncology</i> , 2014 , 32, 7011-7011	2.2	4
150	Second interim analysis of a phase 3 study evaluating idelalisib and rituximab for relapsed CLL.. <i>Journal of Clinical Oncology</i> , 2014 , 32, 7012-7012	2.2	9
149	Phase 2 trial of GS-9973, a selective syk inhibitor, and idelalisib (idela) in chronic lymphocytic leukemia (CLL) and non-Hodgkin lymphoma (NHL).. <i>Journal of Clinical Oncology</i> , 2014 , 32, 7059-7059	2.2	7
148	Health-related quality of life (HRQL) impact of idelalisib (IDELA) in patients (pts) with relapsed chronic lymphocytic leukemia (CLL): Phase 3 results.. <i>Journal of Clinical Oncology</i> , 2014 , 32, 7099-7099	2.2	3
147	Preliminary results of a phase II randomized study (ROMULUS) of polatuzumab vedotin (PoV) or pinatuzumab vedotin (PiV) plus rituximab (RTX) in patients (Pts) with relapsed/refractory (R/R) non-Hodgkin lymphoma (NHL).. <i>Journal of Clinical Oncology</i> , 2014 , 32, 8519-8519	2.2	11
146	CALGB 50803 (Alliance): A phase II trial of lenalidomide plus rituximab in patients with previously untreated follicular lymphoma.. <i>Journal of Clinical Oncology</i> , 2014 , 32, 8521-8521	2.2	11
145	U.S. Intergroup phase II trial (SWOG 1108) of alisertib, an investigational aurora A kinase (AAK) inhibitor, in patients with peripheral T-cell lymphoma (PTCL; NCT01466881).. <i>Journal of Clinical Oncology</i> , 2014 , 32, 8523-8523	2.2	3

144	Letter from the editor. <i>Clinical Advances in Hematology and Oncology</i> , 2014 , 12, 76	0.6	
143	Letter from the editor. <i>Clinical Advances in Hematology and Oncology</i> , 2014 , 12, 152	0.6	
142	Burnout. <i>Clinical Advances in Hematology and Oncology</i> , 2014 , 12, 208	0.6	
141	When I came to the National Cancer Institute. <i>Clinical Advances in Hematology and Oncology</i> , 2014 , 12, 279	0.6	
140	Five Days At Memorial by Dr Sheri Fink. <i>Clinical Advances in Hematology and Oncology</i> , 2014 , 12, 352	0.6	
139	Letter from the Editor. <i>Clinical Advances in Hematology and Oncology</i> , 2014 , 12, 422	0.6	
138	Letter from the editor. <i>Clinical Advances in Hematology and Oncology</i> , 2014 , 12, 496	0.6	
137	Highlights from the 2014 Congress of the European Hematology Association. <i>Clinical Advances in Hematology and Oncology</i> , 2014 , 12, 619-22	0.6	
136	Is ebola scarier than cancer?. <i>Clinical Advances in Hematology and Oncology</i> , 2014 , 12, 718	0.6	
135	Assisted suicide for patients with terminal illness. <i>Clinical Advances in Hematology and Oncology</i> , 2014 , 12, 797	0.6	
134	BEACOPP or no BEACOPP?. <i>Lancet Oncology, The</i> , 2013 , 14, e487-8	21.7	8
133	Intensive chemotherapy and immunotherapy in patients with newly diagnosed primary CNS lymphoma: CALGB 50202 (Alliance 50202). <i>Journal of Clinical Oncology</i> , 2013 , 31, 3061-8	2.2	304
132	Phase III randomized intergroup trial of CHOP plus rituximab compared with CHOP chemotherapy plus (131)iodine-tositumomab for previously untreated follicular non-Hodgkin lymphoma: SWOG S0016. <i>Journal of Clinical Oncology</i> , 2013 , 31, 314-20	2.2	138
131	Therapy for diffuse large B-cell lymphoma: getting personal. <i>Lancet, The</i> , 2013 , 381, 1793-4	40	6
130	The anti-CD80 primatized monoclonal antibody, galiximab, is well-tolerated but has limited activity in relapsed Hodgkin lymphoma: Cancer and Leukemia Group B 50602 (Alliance). <i>Leukemia and Lymphoma</i> , 2013 , 54, 1405-10	1.9	21
129	State-of-the-Art Research on "Lymphomas: Role of Molecular Imaging for Staging, Prognostic Evaluation, and Treatment Response". <i>Frontiers in Oncology</i> , 2013 , 3, 212	5.3	26
128	A phase 2 trial of extended induction epratuzumab and rituximab for previously untreated follicular lymphoma: CALGB 50701. <i>Cancer</i> , 2013 , 119, 3797-804	6.4	37
127	A comparative analysis of prognostic factor models for follicular lymphoma based on a phase III trial of CHOP-rituximab versus CHOP + 131iodine--tositumomab. <i>Clinical Cancer Research</i> , 2013 , 19, 6624-32	12.9	31

126	Safety Profile and Clinical Response To MEDI-551, a Humanized Monoclonal Anti-CD19, In a Phase 1/2 Study In Adults With Relapsed Or Refractory Advanced B-Cell Malignancies. <i>Blood</i> , 2013 , 122, 1810-1810	2.2	12
125	The Utility Of 18f-FDG PET/CT In Assessing Bone Marrow Involvement In Lymphoma. <i>Blood</i> , 2013 , 122, 2981-2981	2.2	2
124	Minimal Residual Disease (MRD) Status Following Induction Chemo-Immunotherapy Predicts Progression-Free Survival In Mantle Cell Lymphoma (MCL): CALGB 50403 (Alliance). <i>Blood</i> , 2013 , 122, 3002-3002	2.2	2
123	The Role Of Body Mass Index In Survival Outcome For Lymphoma Patients: US Intergroup Experience. <i>Blood</i> , 2013 , 122, 3060-3060	2.2	5
122	Evaluation Of a Novel 3 Factor Prognostic Score (PS-3) For Patients With Advanced Hodgkin Lymphoma (HL) Treated On US Intergroup E2496. <i>Blood</i> , 2013 , 122, 4277-4277	2.2	2
121	Final Results Of a Phase I Study Of The Anti-CD22 Antibody-Drug Conjugate (ADC) DCDT2980S With Or Without Rituximab (RTX) In Patients (Pts) With Relapsed Or Refractory (R/R) B-Cell Non-Hodgkin Lymphoma (NHL). <i>Blood</i> , 2013 , 122, 4399-4399	2.2	10
120	A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study Evaluating the Efficacy and Safety of Idelalisib and Rituximab for Previously Treated Patients with Chronic Lymphocytic Leukemia (CLL). <i>Blood</i> , 2013 , 122, LBA-6-LBA-6	2.2	3
119	MEDI-551, an anti-CD19 antibody active in chronic lymphocytic leukemia (CLL) patients previously treated with rituximab.. <i>Journal of Clinical Oncology</i> , 2013 , 31, 7045-7045	2.2	1
118	Improved Risk Stratification With Addition Of Male Sex (S) To The Elderly International Prognostic Index (S-EIPI) For DLBCL Patients > 60 Years Treated With R-CHOP: An International Collaboration Of The US Intergroup, German High-Grade Non-Hodgkin Lymphoma Study Group and Groupe d'Etude De Lymphome d'Adultes. <i>Blood</i> , 2013 , 122, 3045-3045	2.2	1
117	Safe and effective treatment of aggressive non-hodgkin lymphoma with rituximab and bendamustine in patients with severe liver impairment. <i>Clinical Advances in Hematology and Oncology</i> , 2013 , 11, 184-8	0.6	10
116	Complete response to brentuximab vedotin in a transplant-naïve patient with relapsed CD30-positive nodular lymphocyte-predominant Hodgkin lymphoma. <i>Clinical Advances in Hematology and Oncology</i> , 2013 , 11, 382-5	0.6	2
115	Letter from the editor. <i>Clinical Advances in Hematology and Oncology</i> , 2013 , 11, 759	0.6	
114	Letter from the editor. <i>Clinical Advances in Hematology and Oncology</i> , 2013 , 11, 692	0.6	
113	A summer of change in hematologic malignancies: highlights in B-Cell malignancies from the 2013 ASCO, EHA, and ICML meetings. <i>Clinical Advances in Hematology and Oncology</i> , 2013 , 11, 748-50	0.6	
112	The potential for eliminating chemotherapy in indolent non-Hodgkin lymphoma. <i>Clinical Advances in Hematology and Oncology</i> , 2013 , 11 Suppl 14, 5-8	0.6	0
111	Results of a pivotal phase II study of brentuximab vedotin for patients with relapsed or refractory Hodgkin's lymphoma. <i>Journal of Clinical Oncology</i> , 2012 , 30, 2183-9	2.2	1091
110	Novel targeted agents and the need to refine clinical end points in chronic lymphocytic leukemia. <i>Journal of Clinical Oncology</i> , 2012 , 30, 2820-2	2.2	160
109	A Cancer and Leukemia Group B multi-center study of DA-EPOCH-rituximab in untreated diffuse large B-cell lymphoma with analysis of outcome by molecular subtype. <i>Haematologica</i> , 2012 , 97, 758-65	6.6	134

108	A phase II study of the survivin suppressant YM155 in patients with refractory diffuse large B-cell lymphoma. <i>Cancer</i> , 2012 , 118, 3128-34	6.4	80
107	Interim [(18)F]fluorodeoxyglucose positron emission tomography imaging in stage I-II non-bulky Hodgkin lymphoma: would using combined positron emission tomography and computed tomography criteria better predict response than each test alone?. <i>Leukemia and Lymphoma</i> , 2012 , 53, 2143-50	1.9	45
106	Results of a Phase 1 Dose-Escalation Study of Once-Weekly MLN9708, an Investigational Proteasome Inhibitor, in Patients with Relapsed/Refractory Lymphoma. <i>Blood</i> , 2012 , 120, 3646-3646	2.2	3
105	MEDI-551, a Humanized Monoclonal Anti-CD19, in Adults with Relapsed or Refractory Advanced B-Cell Malignancies: Results From a Phase 1/2 Study. <i>Blood</i> , 2012 , 120, 3677-3677	2.2	3
104	Overall Survival Benefit for Patients with Relapsed Hodgkin Lymphoma Treated with Brentuximab Vedotin After Autologous Stem Cell Transplant. <i>Blood</i> , 2012 , 120, 3701-3701	2.2	6
103	A Phase I Study of DCDT2980S, an Antibody-Drug Conjugate (ADC) Targeting CD22, in Relapsed or Refractory B-Cell Non-Hodgkin's Lymphoma (NHL). <i>Blood</i> , 2012 , 120, 59-59	2.2	6
102	CALGB 50401: A randomized trial of lenalidomide alone versus lenalidomide plus rituximab in patients with recurrent follicular lymphoma.. <i>Journal of Clinical Oncology</i> , 2012 , 30, 8000-8000	2.2	12
101	Phase I/II study of MEDI-551, a humanized monoclonal antibody targeting CD19, in subjects with relapsed or refractory advanced B-cell malignancies.. <i>Journal of Clinical Oncology</i> , 2012 , 30, 8065-8065	2.2	1
100	A phase III randomized intergroup trial (S0016) comparing CHOP plus rituximab with CHOP plus iodine-131-tositumomab for front-line treatment of follicular lymphoma: Results of subset analyses and a comparison of prognostic models.. <i>Journal of Clinical Oncology</i> , 2012 , 30, 8001-8001	2.2	
99	Lenalidomide Following Rituximab and Fludarabine in Untreated CLL. <i>Blood</i> , 2012 , 120, 3924-3924	2.2	
98	Cell of Origin in Richter's Transformation of CLL. <i>Blood</i> , 2012 , 120, 4574-4574	2.2	1
97	Differences in Outcomes in Males and Females with Diffuse Large B-Cell Lymphoma with Induction Rituximab and Follicular Lymphoma Treated with Maintenance Rituximab. <i>Blood</i> , 2012 , 120, 3705-3705	2.2	
96	BCL6 Expression and Treatment Delay Correlate with Adverse Outcome in Newly Diagnosed Primary CNS Lymphoma: Final Report of CALGB 50202 (Alliance). <i>Blood</i> , 2012 , 120, 301-301	2.2	
95	New agents in follicular lymphoma. <i>Best Practice and Research in Clinical Haematology</i> , 2011 , 24, 305-12	4.2	9
94	Doxorubicin, vinblastine, and gemcitabine (CALGB 50203) for stage I/II nonbulky Hodgkin lymphoma: pretreatment prognostic factors and interim PET. <i>Blood</i> , 2011 , 117, 5314-20	2.2	52
93	Bortezomib, bendamustine, and rituximab in patients with relapsed or refractory follicular lymphoma: the phase II VERTICAL study. <i>Journal of Clinical Oncology</i> , 2011 , 29, 3389-95	2.2	91
92	Role of functional imaging in the management of lymphoma. <i>Journal of Clinical Oncology</i> , 2011 , 29, 1844-54	2.2	211
91	Efficacy of bendamustine in rituximab-refractory indolent B-cell non-Hodgkin lymphoma: review of a pivotal trial. <i>Future Oncology</i> , 2011 , 7, 9-14	3.6	4

90	Genetic abnormalities in CLL: prognostic factors--or their own disease?. <i>Oncology</i> , 2011 , 25, 706, 708	1.8	
89	Accurate reporting of adverse events in chronic lymphocytic leukemia and non-Hodgkin lymphoma. <i>Clinical Advances in Hematology and Oncology</i> , 2011 , 9, 1-11	0.6	
88	Bendamustine: mechanism of action and clinical data. <i>Clinical Advances in Hematology and Oncology</i> , 2011 , 9, 1-11	0.6	8
87	The 51st annual meeting of the American Society of Hematology. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2010 , 10, 11-20	2	1
86	Optimal use of bendamustine in chronic lymphocytic leukemia, non-Hodgkin lymphomas, and multiple myeloma: treatment recommendations from an international consensus panel. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2010 , 10, 21-7	2	75
85	The sarcoid-lymphoma syndrome. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2010 , 10, 241-7	2	27
84	Bendamustine produces durable responses with an acceptable safety profile in patients with rituximab-refractory indolent non-Hodgkin lymphoma. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2010 , 10, 452-7	2	43
83	Bendamustine in chronic lymphocytic leukemia and non-Hodgkin's lymphoma. <i>Expert Review of Anticancer Therapy</i> , 2010 , 10, 1353-65	3.5	6
82	Ofatumumab, a novel anti-CD20 monoclonal antibody for the treatment of B-cell malignancies. <i>Journal of Clinical Oncology</i> , 2010 , 28, 3525-30	2.2	135
81	Monoclonal antibody therapy of chronic lymphocytic leukaemia. <i>Best Practice and Research in Clinical Haematology</i> , 2010 , 23, 133-43	4.2	16
80	Bendamustine is effective therapy in patients with rituximab-refractory, indolent B-cell non-Hodgkin lymphoma: results from a Multicenter Study. <i>Cancer</i> , 2010 , 116, 106-14	6.4	194
79	Author reply: Rituximab maintenance for follicular lymphoma. <i>Nature Reviews Clinical Oncology</i> , 2010 , 7, 1-1	19.4	
78	Syk [sic] of the same old chemotherapy?. <i>Blood</i> , 2010 , 115, 2561-2	2.2	2
77	Response: Defining response criteria in CLL patients treated in clinical research trials. <i>Blood</i> , 2010 , 116, 1817-1818	2.2	1
76	Targeted treatment and new agents in follicular lymphoma. <i>International Journal of Hematology</i> , 2010 , 92, 5-11	2.3	5
75	Combination Biologic Therapy as Initial Treatment for Follicular Lymphoma: Initial Results From CALGB 50701 - a Phase II Trial of Extended Induction Epratuzumab (anti-CD22) and Rituximab (anti-CD20). <i>Blood</i> , 2010 , 116, 427-427	2.2	6
74	R-CHOP Versus (vs) CHOP Followed by Maintenance Rituximab (MR) Vs Observation In Older Diffuse Large B-Cell Lymphoma (DLBCL) Patients (pts): Long-Term Follow-up of Intergroup E4494/C9793. <i>Blood</i> , 2010 , 116, 589-589	2.2	6
73	Intensive Chemotherapy and Immunotherapy, without Brain Irradiation, In Newly Diagnosed Patients with Primary CNS Lymphoma: Results of CALGB 50202. <i>Blood</i> , 2010 , 116, 763-763	2.2	3

72	Letter from the editor. <i>Clinical Advances in Hematology and Oncology</i> , 2010 , 8, 144	0.6	
71	Bendamustine: rebirth of an old drug. <i>Journal of Clinical Oncology</i> , 2009 , 27, 1492-501	2.2	194
70	Novel therapies for peripheral T-cell non-Hodgkin's lymphomas. <i>Current Opinion in Hematology</i> , 2009 , 16, 299-305	3.3	19
69	Phase I study of obatoclox mesylate (GX15-070), a small molecule pan-Bcl-2 family antagonist, in patients with advanced chronic lymphocytic leukemia. <i>Blood</i> , 2009 , 113, 299-305	2.2	238
68	Bendamustine Produces Durable Responses with An Acceptable Long-Term Safety Profile in Patients with Rituximab-Refractory Non-Hodgkin's Lymphoma: A Pooled Analysis.. <i>Blood</i> , 2009 , 114, 2681-2681	2.2	4
67	Lenalidomide Alone and in Combination with Rituximab Enhances NK Cell Immune Synapse Formation in Chronic Lymphocytic Leukemia (CLL) Cells in Vitro through Activation of Rho and Rac1 GTPases.. <i>Blood</i> , 2009 , 114, 3441-3441	2.2	6
66	A Phase I Study of PRO131921, a Novel Anti-CD20 Monoclonal Antibody in Patients with Relapsed/Refractory CD20+ Indolent NHL: Correlation Between Clinical Responses and AUC Pharmacokinetics.. <i>Blood</i> , 2009 , 114, 3742-3742	2.2	5
65	Etiology and management of tumor lysis syndrome in patients with chronic lymphocytic leukemia. <i>Clinical Advances in Hematology and Oncology</i> , 2009 , 7, 263-71	0.6	14
64	Bendamustine induced neurotoxicity. <i>Clinical Advances in Hematology and Oncology</i> , 2009 , 7, 743-6	0.6	11
63	Thalidomide has limited single-agent activity in relapsed or refractory indolent non-Hodgkin lymphomas: a phase II trial of the Cancer and Leukemia Group B. <i>British Journal of Haematology</i> , 2008 , 140, 313-9	4.5	21
62	Staging and evaluation of the patient with lymphoma. <i>Hematology/Oncology Clinics of North America</i> , 2008 , 22, 825-37, vii-viii	3.1	21
61	Meeting Highlights. <i>Clinical Lymphoma and Myeloma</i> , 2008 , 8, 210-218		
60	Phase II multicenter study of bendamustine plus rituximab in patients with relapsed indolent B-cell and mantle cell non-Hodgkin's lymphoma. <i>Journal of Clinical Oncology</i> , 2008 , 26, 4473-9	2.2	293
59	Bendamustine in patients with rituximab-refractory indolent and transformed non-Hodgkin's lymphoma: results from a phase II multicenter, single-agent study. <i>Journal of Clinical Oncology</i> , 2008 , 26, 204-10	2.2	243
58	Guidelines for the diagnosis and treatment of chronic lymphocytic leukemia: a report from the International Workshop on Chronic Lymphocytic Leukemia updating the National Cancer Institute-Working Group 1996 guidelines. <i>Blood</i> , 2008 , 111, 5446-56	2.2	2531
57	New staging and response criteria for non-Hodgkin lymphoma and Hodgkin lymphoma. <i>Radiologic Clinics of North America</i> , 2008 , 46, 213-23, vii	2.3	28
56	Lenalidomide for the treatment of B-cell malignancies. <i>Journal of Clinical Oncology</i> , 2008 , 26, 1544-52	2.2	159
55	A phase I study of the pan bcl-2 family inhibitor obatoclox mesylate in patients with advanced hematologic malignancies. <i>Clinical Cancer Research</i> , 2008 , 14, 8295-301	12.9	168

54	Needle tract seeding after bone marrow biopsy in non-Hodgkin lymphoma. <i>Leukemia and Lymphoma</i> , 2008 , 49, 156-8	1.9	15
53	Monoclonal antibody therapy for B-cell non-Hodgkin's lymphoma. <i>New England Journal of Medicine</i> , 2008 , 359, 613-26	59.2	352
52	FLIPI Score Is Applicable and Predictive of Response to Upfront Immunotherapy in CALGB 50402: Phase II Trial of Extended Induction Galiximab ([G] anti-CD80 monoclonal antibody) Plus Rituximab [R].. <i>Blood</i> , 2008 , 112, 1003-1003	2.2	4
51	Phase I Dose-Escalation Trial of BI 2536, a Polo-Like Kinase 1 Inhibitor, in Relapsed and Refractory Non-Hodgkin's Lymphoma. <i>Blood</i> , 2008 , 112, 233-233	2.2	6
50	Ghostwriting. <i>Clinical Advances in Hematology and Oncology</i> , 2008 , 6, 318	0.6	
49	Bendamustine: a new therapeutic option for hematologic malignancies. <i>Clinical Advances in Hematology and Oncology</i> , 2008 , 6, 631-3	0.6	1
48	Adult Burkitt lymphoma: too soon to declare victory. <i>Oncology</i> , 2008 , 22, 1518-9	1.8	
47	Overcoming mechanisms of RESISTance in lymphoma. <i>Leukemia and Lymphoma</i> , 2007 , 48, 447-8	1.9	1
46	Single agent bortezomib in the treatment of relapsed and refractory Hodgkin lymphoma: cancer and leukemia Group B protocol 50206. <i>Leukemia and Lymphoma</i> , 2007 , 48, 1313-9	1.9	57
45	Revised response criteria for malignant lymphoma. <i>Journal of Clinical Oncology</i> , 2007 , 25, 579-86	2.2	3483
44	The International Harmonization Project for response criteria in lymphoma clinical trials. <i>Hematology/Oncology Clinics of North America</i> , 2007 , 21, 841-54	3.1	99
43	Clinical management of T-cell malignancies: current perspectives, key issues, and emerging therapies. <i>Seminars in Oncology</i> , 2007 , 34, S3-7	5.5	7
42	Is BEACOPP better than ABVD?. <i>Current Hematologic Malignancy Reports</i> , 2007 , 2, 161-6	4.4	7
41	Use of positron emission tomography for response assessment of lymphoma: consensus of the Imaging Subcommittee of International Harmonization Project in Lymphoma. <i>Journal of Clinical Oncology</i> , 2007 , 25, 571-8	2.2	1113
40	The role of FDG-PET scans in patients with lymphoma. <i>Blood</i> , 2007 , 110, 3507-16	2.2	245
39	Results of a phase II study of 506U78 in cutaneous T-cell lymphoma and peripheral T-cell lymphoma: CALGB 59901. <i>Leukemia and Lymphoma</i> , 2007 , 48, 97-103	1.9	36
38	Bendamustine Is Safe and Effective in Patients with Rituximab-Refractory, Indolent B-Cell Non-Hodgkin Lymphoma.. <i>Blood</i> , 2007 , 110, 1351-1351	2.2	5
37	A Phase I Trial of the Small Molecule Pan-Bcl-2 Family Inhibitor Obatoclax Mesylate (GX15-070) Administered by Continuous Infusion for up to Four Days to Patients with Hematological Malignancies.. <i>Blood</i> , 2007 , 110, 892-892	2.2	4

36	Oblimersen for the treatment of patients with chronic lymphocytic leukemia. <i>Therapeutics and Clinical Risk Management</i> , 2007 , 3, 855-70	2.9	31
35	Emerging treatments for indolent lymphoma. <i>Clinical Advances in Hematology and Oncology</i> , 2007 , 5, 1-9; quiz 11-2	0.6	2
34	Monoclonal antibody therapy of chronic lymphocytic leukemia. <i>Cancer Immunology, Immunotherapy</i> , 2006 , 55, 188-96	7.4	39
33	Monoclonal antibody therapy for B-cell malignancies. <i>Seminars in Oncology</i> , 2006 , 33, S2-14	5.5	38
32	The cancer and leukemia group B lymphoma committee. <i>Clinical Cancer Research</i> , 2006 , 12, 3572s-5s	12.9	1
31	Positron-emission tomography and assessment of cancer therapy. <i>New England Journal of Medicine</i> , 2006 , 354, 496-507	59.2	601
30	Clinical application and proposal for modification of the International Working Group (IWG) response criteria in myelodysplasia. <i>Blood</i> , 2006 , 108, 419-25	2.2	1125
29	Radioimmunotherapy of non-Hodgkin's lymphomas. <i>Current Drug Targets</i> , 2006 , 7, 1293-300	3	21
28	Phase II Results of Bendamustine in Combination with Rituximab in Relapsed Indolent and Mantle-Cell Non-Hodgkin's Lymphoma.. <i>Blood</i> , 2006 , 108, 2710-2710	2.2	6
27	Immuno-Chemotherapy (IC) and Autologous Stem Cell Transplant (ASCT) for Untreated Patients (pts) with Mantle Cell Lymphoma (MCL): CALGB 59909.. <i>Blood</i> , 2006 , 108, 2737-2737	2.2	3
26	The Impact of GM-CSF on Arsenic Trioxide (As ₂ O ₃ , Trisenox) Therapy in Patients with Myelodysplastic Syndrome (MDS): Preliminary Results of a Phase II Study.. <i>Blood</i> , 2006 , 108, 4856-4856	2.2	1
25	CLL response criteria. <i>Clinical Advances in Hematology and Oncology</i> , 2006 , 4, 4-5; discussion 10; suppl 12	0.6	
24	The role of radioimmunotherapy with yttrium-90 ibritumomab tiuxetan in the treatment of non-Hodgkin lymphoma. <i>BioDrugs</i> , 2005 , 19, 309-22	7.9	13
23	The progress and promise of molecular imaging probes in oncologic drug development. <i>Clinical Cancer Research</i> , 2005 , 11, 7967-85	12.9	194
22	Response assessment of aggressive non-Hodgkin's lymphoma by integrated International Workshop Criteria and fluorine-18-fluorodeoxyglucose positron emission tomography. <i>Journal of Clinical Oncology</i> , 2005 , 23, 4652-61	2.2	314
21	Revised Response Criteria for Malignant Lymphomas From the Members of the International Harmonization Project (IHP) of the Competence Network Malignant Lymphoma, Represented by:.. <i>Blood</i> , 2005 , 106, 18-18	2.2	5
20	A Phase I Trial of the Small Molecule Pan-Bcl-2 Family Inhibitor GX15-070 Administered Intravenously (IV) Every 3 Weeks to Patients with Previously Treated Chronic Lymphocytic Leukemia (CLL).. <i>Blood</i> , 2005 , 106, 446-446	2.2	13
19	Development of a Measure of Health-Related Quality of Life for Non-Hodgkin's Lymphoma Clinical Research: The Functional Assessment of Cancer Therapy - Lymphoma (FACT-Lym).. <i>Blood</i> , 2005 , 106, 750-750	2.2	17

18	SGN-30 (Anti-CD30 Monoclonal Antibody) Is Active and Well Tolerated in Patients with Refractory or Recurrent Systemic Anaplastic Large Cell Lymphoma (ALCL).. <i>Blood</i> , 2005 , 106, 3356-3356	2.2	1
17	Flow Cytometric Analysis in Myelodysplastic Syndrome (MDS).. <i>Blood</i> , 2005 , 106, 4932-4932	2.2	
16	Treatment Outcomes in Patients (Pts) with Transformed Chronic Lymphocytic Leukemia (CLL) in One Institution.. <i>Blood</i> , 2005 , 106, 5031-5031	2.2	
15	Managing malignancy-associated hyperuricemia with rasburicase. <i>The Journal of Supportive Oncology</i> , 2005 , 3, 117-24		9
14	Phase II Study of SGN-30 (Anti-CD30 Monoclonal Antibody) in Patients with Refractory or Recurrent Hodgkin's Disease.. <i>Blood</i> , 2004 , 104, 2635-2635	2.2	9
13	Phase II Study of Thalidomide in Escalating Doses for Follicular (F-NHL) and Small Lymphocytic Lymphoma (SLL): CALGB Study 50002.. <i>Blood</i> , 2004 , 104, 3284-3284	2.2	4
12	Deletion of 13q14 Is Independent of CD38 Expression in Chronic Lymphocytic Leukemia (CLL).. <i>Blood</i> , 2004 , 104, 4807-4807	2.2	
11	ZAP-70 Expression in Chronic Lymphocytic Leukemia (CLL) Is Independent of Rai Stage: A Retrospective Review of 38 Patients (pts).. <i>Blood</i> , 2004 , 104, 4811-4811	2.2	
10	Overview of the revised response criteria for acute myelogenous leukemia. <i>Clinical Advances in Hematology and Oncology</i> , 2004 , 2, 277-9	0.6	4
9	Radioimmunotherapy of non-Hodgkin lymphomas. <i>Blood</i> , 2003 , 101, 391-8	2.2	137
8	Revised recommendations of the International Working Group for Diagnosis, Standardization of Response Criteria, Treatment Outcomes, and Reporting Standards for Therapeutic Trials in Acute Myeloid Leukemia. <i>Journal of Clinical Oncology</i> , 2003 , 21, 4642-9	2.2	2107
7	Dose-adjusted EPOCH chemotherapy for untreated large B-cell lymphomas: a pharmacodynamic approach with high efficacy. <i>Blood</i> , 2002 , 99, 2685-93	2.2	249
6	Rituximab treatment of refractory fludarabine-associated immune thrombocytopenia in chronic lymphocytic leukemia. <i>Blood</i> , 2002 , 100, 2260-2262	2.2	71
5	Rituximab treatment of refractory fludarabine-associated immune thrombocytopenia in chronic lymphocytic leukemia. <i>Blood</i> , 2002 , 100, 2260-2	2.2	17
4	Fludarabine compared with chlorambucil as primary therapy for chronic lymphocytic leukemia. <i>New England Journal of Medicine</i> , 2000 , 343, 1750-7	59.2	840
3	Report of an international workshop to standardize response criteria for non-Hodgkin's lymphomas. NCI Sponsored International Working Group. <i>Journal of Clinical Oncology</i> , 1999 , 17, 1244	2.2	2910
2	Superiority of Tandem Autologous Transplantation Over Standard Therapy for Previously Untreated Multiple Myeloma. <i>Blood</i> , 1997 , 89, 789-793	2.2	468
1	International staging and response criteria for lymphomas 277-285		

